The North American nuclear medicine/radiopharmaceuticals market was worth almost $2 billion in 2015 and is expected to reach about $3 billion by 2020, according to a market report from Reportlinker. The aging population, growing prevalence of cancer, interest in hybrid imaging, the rise in public awareness, abundance of radiopharmaceuticals and technological advancements are contributing to the growth in the market, according to MD Buyline.
FDG is the most widely used radiopharmaceutical on the market, and with more facilities making it the price is decreasing. Big commercial entities are producing it in larger volumes. “Some academic sites are stepping away from that because the commercial entities can make large batches and can distribute it to the hospitals that need it,” says Suzanne Lapi, president of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Radiopharmaceutical Sciences Council. Read more.